Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook


 


 

23andMe only heightens the need for genetic counselling

02 February 2015

By Dr Joyce Harper

Professor of human genetics and embryology at the Institute for Women’s Health at University College London

Appeared in BioNews 788

Partially out of curiosity and partially as an assignment for Radio 4's PM show, I was one of the first to 'get to know me', as their company slogan goes, and have my genome analysed by 23andMe.

23andMe offer direct-to-consumer DNA analysis. Customers order a collection kit over the internet - essentially a tube you spit into and return to the company. About six weeks later the results arrive by email. At no point is there any involvement from a physician or genetic counsellor to explain what is being tested for or the consequences of the results.

23andMe use a single nucleotide polymorphism (SNP) array that tests for markers in five different categories: genes leading to inherited conditions, genetic risks, traits, genes affecting drug response and ancestry. The service costs £125 per person. I think most people taking this test are going to assume that nothing will show up - as I did.

Genetic conditions are very complex, even when there's just one faulty gene involved. For example, over 1,000 different mutations can give rise to cystic fibrosis. 23andMe only tests for one or a few mutations in each gene, so using this test does not mean that you are not at risk of the disease they are testing for.

Many genetic diseases are multifactorial; they can be affected by both genes and environment, and some disorders show varying penetrance, so carrying the faulty gene does not necessarily mean you will get the disorder. As you can see, it's complicated.

All of the 43 inherited conditions in this test are recessive, so to have the disorder you would need to inherit two faulty genes; one each from your mother and father. The majority of the disorders they test for are early onset, so any adult taking the test should already know that they have the condition. Included in the 43 genes are a large number of very rare inherited conditions for someone with a European ancestry, such as Gaucher disease and maple syrup urine disease, both of which are common in those of Ashkenazi Jewish ancestry.

Eleven genetic risk genes are tested by 23andMe, including Alzheimer's, Parkinson's, and the breast and ovarian cancer risk genes BRCA1 and 2.

In my view, 23andMe should not include these three disorders on their genetic testing panel. Due to the potentially life-altering nature of the test results, 23andMe have 'locked' these results, but unfortunately this only means that you need to do two extra clicks to gain access. Once you know your genetic status for these disorders, the information cannot be taken back.

The 23andMe test for the BRCA1 and 2 genes are unlikely to be positive for someone of European decent as they only test for the three common mutations affecting Ashkenazi Jews. Also, the majority of breast cancer is not genetically inherited and so even if someone is free of BRCA1 and 2 mutations, it does not mean you will not get breast or ovarian cancer.

Parkinson's is a serious disorder of the brain's motor centre and current treatment is effective in few people but only ever serves to slow the disorder, not cure it. A friend recently diagnosed with Parkinson's told me that he is glad he did not know they were at risk before their diagnosis.

And then Alzheimer's has no treatment or cure. I would have preferred to have opted out of receiving this information but this was not possible.

The other genes assessed in the genetic risk section are not as controversial and include hypertrophic cardiomyopathy and inherited thrombophilia (factor V Leiden), which increases the risk of deep vein thrombosis. I discovered that I was at five times the risk of getting deep vein thrombosis, but I could not find anywhere what the base value was. I have already been emailed by a company selling compression stockings!

23andMe look at 40 genetic traits which cover a range of random, mainly useless information, including breast morphology, how many teeth at age 12, birth weight, bitter taste perception, eye colour, earwax type, age of first period, red hair and pain sensitivity - you get the idea. I found out I was lactose intolerant and had increased pain sensitivity, the significance of which is debatable.

The test also analyses 12 genetic variations related to how people respond to drugs. These may indicate differences in sensitivity or in the likelihood or severity of side effects. This is quite complex information, which would need to be decoded by a physician and is only relevant if you were having a particular drug treatment.

For ancestry, 23andMe determines what percentage of your DNA comes from 31 populations worldwide. I found that I was 68 percent European and 28 percent South Asian. This information can be shared with others on the 23andMe database, anonymously or named, and some people have found close relatives. I only had third to sixth cousins in the database.

For me, having my DNA analysed by 23andMe was an interesting experience but it took me several days to go through the overwhelming amount of genetic information I was supplied with (and I know something about genetics!)

I found the web site difficult to navigate and the information of varying quality. I cannot imagine what a person who knows little about genetics would gain from this information – confusion, stress, anxiety? Some of the information is benign, but some is sensitive and cannot be taken lightly.

Direct-to-consumer genetic analysis is on the rise and people should be given the opportunity to 'personalise' their results so that any unwanted information on genetic disorders or risk is not divulged.

The Holy Grail will be next-generation sequencing which can read the full sequence of your genetic code and this is already offered over the internet. Sequencing is also performed for non-invasive prenatal testing at around ten weeks of pregnancy (this has not yet been fully rolled out across the NHS), but currently only looks at a few chromosomes of the fetus. In the future it should be possible to test the full genome during pregnancy so every child will be born knowing their genetic code. It is essential that the role of the genetic counsellor be embraced so that the full potential of this information is understood.

SOURCES & REFERENCES

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

03 May 2016 - by Professor Joyce Harper, Debbie Kennett and Dr Dan Reisel 
With the rise of consumer genetic testing, it is now possible for people to accidentally discover that they were conceived using donor eggs or sperm and for donors who thought they were anonymous to be traced by their offspring...
24 August 2015 - by Professor Sandy Raeburn 
Over 30 years ago, those who taught clinical genetics to medical students and other health professionals focussed on the triple difficulty of explaining a genetic disease, its inheritance pattern and its scientific basis. Now, there is a growing literature of personal memoirs, wonderfully exemplified by this splendid monograph...
17 August 2015 - by James Brooks 
23andMe, the biomedical wing of the industrial personal-data complex, has produced a board book for toddlers. The End Times draw near...
16 March 2015 - by Arit Udoh 
US-based genetic testing company, 23andMe, has announced plans to use its customers' data for research and drug development...
02 March 2015 - by Alice Hazelton 
Genome sequencing offers great potential for the effective diagnosis and future treatment of many conditions. But while the excitement continues to grow around the science, few have stopped to ask what patients, the ultimate end-beneficiaries of this technology, think...

15 December 2014 - by Dr Jess Buxton 
This discussion around the role of commerce in genetics and fertility treatment coincided with the launch of 23andMe's controversial personal genome service in the UK. Issues around health interventions following personal genetic testing were the focus of the second session at PET's conference, which asked: 'Whose genes are they anyway?'...
08 December 2014 - by Arit Udoh 
US-based genetic testing company 23andMe has launched its controversial 'personal genome service' in the UK...
12 December 2013 - by Dr Ruth Stirton 
23andMe and UK Biobank are both large genetic databases: big enough to engage in serious population genetic research. But 23andMe has not undergone any ethical approval processes - think what they could do if they sold their database...
09 December 2013 - by Ruth Saunders 
Genetic testing company 23andMe, which last week suspended the sale of its health-related genetic tests, is now facing a class action lawsuit in California over its marketing claims....

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Andy Greenfield

Dr Anna Smajdor

Dr Henry Malter

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross

Sandy Starr


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation